| Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in … L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Caliò, ... PloS one 10 (6), e0130142, 2015 | 492 | 2015 |
| Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for … M Simbolo, A Mafficini, KO Sikora, M Fassan, S Barbi, V Corbo, ... The Journal of pathology 241 (4), 488-500, 2017 | 182 | 2017 |
| Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC I Chaib, N Karachaliou, S Pilotto, J Codony Servat, X Cai, X Li, ... JNCI: Journal of the National Cancer Institute 109 (9), djx014, 2017 | 137 | 2017 |
| Role of mTOR signaling in tumor microenvironment: an overview F Conciatori, C Bazzichetto, I Falcone, S Pilotto, E Bria, F Cognetti, ... International Journal of Molecular Sciences 19 (8), 2453, 2018 | 123 | 2018 |
| mTOR cross-talk in cancer and potential for combination therapy F Conciatori, L Ciuffreda, C Bazzichetto, I Falcone, S Pilotto, E Bria, ... Cancers 10 (1), 23, 2018 | 116 | 2018 |
| Physical activity and exercise in lung cancer care: will promises be fulfilled? A Avancini, G Sartori, A Gkountakos, M Casali, I Trestini, D Tregnago, ... The oncologist 25 (3), e555-e569, 2020 | 107 | 2020 |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ... European Journal of Cancer 130, 155-167, 2020 | 93 | 2020 |
| Cellular and molecular biology of small cell lung cancer: an overview N Karachaliou, S Pilotto, C Lazzari, E Bria, F de Marinis, R Rosell Translational lung cancer research 5 (1), 2, 2016 | 87 | 2016 |
| Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations M Simbolo, S Barbi, M Fassan, A Mafficini, G Ali, C Vicentini, N Sperandio, ... Journal of Thoracic Oncology 14 (9), 1651-1661, 2019 | 81 | 2019 |
| PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around A Gkountakos, G Sartori, I Falcone, G Piro, L Ciuffreda, C Carbone, ... Cancers 11 (8), 1141, 2019 | 80 | 2019 |
| High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers M Fassan, M Simbolo, E Bria, A Mafficini, S Pilotto, P Capelli, ... Gastric cancer 17, 442-449, 2014 | 70 | 2014 |
| Do immune checkpoint inhibitors need new studies methodology? R Ferrara, S Pilotto, M Caccese, G Grizzi, I Sperduti, D Giannarelli, ... Journal of thoracic disease 10 (Suppl 13), S1564, 2018 | 66 | 2018 |
| Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives MG Ferrara, V Di Noia, E D’Argento, E Vita, P Damiano, A Cannella, ... Cancers 12 (5), 1196, 2020 | 64 | 2020 |
| ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung A Caliò, A Nottegar, E Gilioli, E Bria, S Pilotto, U Peretti, S Kinspergher, ... Journal of Thoracic Oncology 9 (5), 729-732, 2014 | 63 | 2014 |
| Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm G Pelosi, F Bianchi, E Dama, M Simbolo, A Mafficini, A Sonzogni, S Pilotto, ... Virchows Archiv 472, 567-577, 2018 | 62 | 2018 |
| BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer N Karachaliou, J Codony-Servat, C Teixidó, S Pilotto, A Drozdowskyj, ... Scientific reports 5 (1), 17499, 2015 | 62 | 2015 |
| Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer F Loupakis, R Moretto, G Aprile, M Muntoni, C Cremolini, D Iacono, ... British journal of cancer 114 (1), 30-36, 2016 | 61 | 2016 |
| Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma E Bria, S Pilotto, E Amato, M Fassan, S Novello, U Peretti, T Vavalà, ... Oncotarget 6 (14), 12783, 2015 | 61 | 2015 |
| ROS1-rearranged non–small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS) R Chiari, B Ricciuti, L Landi, AM Morelli, A Delmonte, G Spitaleri, ... Clinical Lung Cancer 21 (1), 15-20, 2020 | 60 | 2020 |
| Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: sensitivity analysis of randomized trials in adjuvant … L Carbognin, S Pilotto, R Nortilli, M Brunelli, A Nottegar, I Sperduti, ... The oncologist 21 (3), 283-291, 2016 | 59 | 2016 |
